Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer: Cyclin-dependent kinases 4 and 6 (CDK4/6) have emerged as important targets in the treatment of breast cancer, given their role in cell-cycle progression and the successes that inhibitors of these kinases have had in improving outcomes in patients with advanced breast cancer. Ribociclib is one of…